About: http://data.cimple.eu/news-article/803fdea440a5ff3a688b98117657adeb75f4b366dbc171a7cabe2ee5

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: http://data.cimple.eu/news-article/803fdea440a5ff3a688b98117657adeb75f4b366dbc171a7cabe2ee5 Goto Sponge NotDistinct Permalink

An Entity of Type : schema:NewsArticle, within Data Space : data.cimple.eu associated with source document(s)

Attributes	Values
rdf:type	schema:NewsArticle
schema:articleBody	The experimental drug remdesivir has been authorized by US regulators for emergency use against COVID-19, President Donald Trump announced Friday. It comes after the antiviral made by Gilead Sciences was shown in a major clinical trial to shorten the time to recovery in some coronavirus patients, the first time any medicine has had a proven benefit against the disease. "It is really a really promising situation," Trump said at the White House, where he was joined by Gilead's CEO Daniel O'Day. "We are humbled with this first step for hospitalized patients," said O'Day, adding: "We want to make sure nothing gets in the way of these patients getting the medicine." The company has previously announced it was donating some 1.5 million doses for free. This amounts to about 140,000 treatment courses based on a 10-day treatment duration. Remdesivir, which is administered by an injection, was already available to some patients who enrolled in clinical trials, or who sought it out on a "compassionate use" basis. The new move allows it to be distributed far more widely and used in both adults and children who are hospitalized with a severe form of COVID-19. The Food and Drug Administration, which authorized the approval, defines severe as having low blood oxygen levels, requiring oxygen therapy, or being on a ventilator. The US National Institute of Allergy and Infectious Diseases (NIAID) announced the results of a trial involving more than 1,000 people on Wednesday. It found that hospitalized COVID-19 patients with respiratory distress got better quicker than those on a placebo. Specifically, patients on the drug had a 31 percent faster time to recovery. "Although the results were clearly positive from a statistically significant standpoint, they were modest," Anthony Fauci, the scientist who leads the NIAID told NBC News on Thursday. While not considered a miracle cure, remdesivir's trial achieved a "proof of concept," according to Fauci that could pave the way for better treatments. Remdesivir incorporates itself into the virus's genome, short circuiting its replication process. It was first developed to treat Ebola, a viral hemorrhagic fever, but did not boost survival rates as other medicines. bur-ia/ec
schema:headline	US issues emergency approval for remdesivir for COVID-19 patients
schema:mentions	Shortness of breath Oxygen therapy NBC News Clinical trial Antiviral drug Placebo Remdesivir Medication National Institute of Allergy and Infectious Diseases Allergy Ebola virus disease Presidency of Donald Trump Anthony S. Fauci Chief executive officer Virus Severe acute respiratory syndrome coronavirus 2 President of the United States Donald Trump Darren O'Day Daniel O'Day Viral hemorrhagic fever Gilead Sciences EC (programming language)
schema:author	http://data.cimple.eu/organization/1f0054d541e000623a2c1e561a247c073ef6328e8be9ffafda7b3fcd
schema:datePublished	2020-05-01 (xsd:date)
http://data.cimple...sPoliticalLeaning	other political leaning
http://data.cimple...logy#hasSentiment	neutral sentiment
http://data.cimple...readability_score	79 (xsd:integer)
http://data.cimple...tology#hasEmotion	happiness

Faceted Search & Find service v1.16.115 as of Oct 09 2023

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3238 as of Jul 16 2024, on Linux (x86_64-pc-linux-musl), Single-Server Edition (126 GB total memory, 5 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software